Riluzole for the treatment of amyotryophic lateral sclerosis: an assessment of clinical efficacy and safety
Garces K, Husereau D, Skidmore B, Turnbull J
Record ID 32003001148
English, French
Authors' objectives:
Overall objective: to assess the potential benefits and harms of riluzole for the treatment of patients with ALS. Specific objectives: to assess the effect of riluzole on mortality, morbidity, and quality of life for patients with ALS.
Authors' recommendations:
Riluzole has the potential to reduce serious morbidity in certain patients at the cost of causing some drug intolerance (withdrawals due to adverse events). There is no information available to describe its impact on quality of life or time to tracheostomy alone.
Authors' methods:
Systematic review
Details
Project Status:
Completed
URL for project:
https://www.ccohta.ca/
Year Published:
2003
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Amyotrophic Lateral Sclerosis
- Riluzole
Contact
Organisation Name:
Canadian Coordinating Office for Health Technology Assessment
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Coordinating Office for Health Technology Assessment (CCOHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.